JPMorgan Nasdaq Equity Premium Income ETF vs Koninklijke Philips NV — how do they compare? JPMorgan Nasdaq Equity Premium Income ETF trades at $59.68, while Koninklijke Philips NV trades at $26.58 (market cap $26.19B). The key difference: Koninklijke Philips NV pays a 3.79% dividend while JPMorgan Nasdaq Equity Premium Income ETF pays none, and JPMorgan Nasdaq Equity Premium Income ETF is trading nearer its 52-week high, Koninklijke Philips NV nearer its low. Which is the better fit depends on your goals.
| JEPQ | PHG | |
|---|---|---|
Sector | Income / Options Overlay | Health |
52-Week High | $61.46 | $32.91 |
52-Week Low | $53.77 | $24.54 |
Market Cap | — | $26.19B |
Enterprise Value | — | $32.46B |
Dividend Yield | — | 3.79% |
Signals from Pluang's Aura AI — not financial advice
JEPQ trades at $58.59, up 0.14% with a bearish technical signal from moving averages. The ETF focuses on Nasdaq-100 exposure with covered-call strategies, generating monthly income through dividends. Recent distributions include $0.64, $0.56, and $0.59 per share, highlighting its income-oriented approach. Technical indicators show neutral oscillators but overall bearish momentum with key support at $57.
The outlook remains cautious due to technical bearishness and capped upside from covered calls. Investment appeal centers on high distribution yields for income-focused investors, though performance may lag pure Nasdaq-100 ETFs during rallies. Risks include strategy underperformance in bull markets and dependency on options income sustainability.
PHG trades at $26.80, down 0.56% with bearish technical signals. The company shows improved fundamentals with net income turning positive to $895M in 2025 after previous losses, though revenue declined slightly to $17.83B. Analyst consensus is mixed with 40.9% buy ratings but technical indicators show selling pressure. Recent developments include FDA clearances for AI-powered medical devices and strategic healthcare partnerships.
PHG presents a turnaround story with profitability recovery but faces execution risks amid competitive pressures. The stock offers value at reasonable valuations (P/E 23.67, P/S 1.29) but requires monitoring of revenue stabilization and AI product adoption. Near-term catalyst includes Q2 2026 earnings with expected EPS of $0.40.
Trailing returns across standard periods
Latest headlines on both assets
JEPQ seeks to provide monthly income and exposure to the Nasdaq-100 Index with less volatility. It uses a methodology that combines high-growth tech stocks with an options strategy to capture income.
Read more on JEPQ →Philips is a diversified global healthcare company operating in three segments: diagnosis and treatment, connected care, and personal health. About 50% of the company's revenue comes from the diagnosis and treatment segment, which features imaging systems, ultrasound equipment, image-guided therapy solutions and healthcare informatics. The connected care segment (27% of revenue) encompasses monitoring and analytics systems for hospitals and sleep and respiratory care devices, whereas the personal health business (remainder of revenue) includes electric toothbrushes and men's grooming and personal-care products. In 2021, Philips generated EUR 17.2 billion in sales and had 80,000 employees in over 100 countries.
Read more on PHG →